Physicians' Knowledge About FDA Approval Standards and Perceptions of the "Breakthrough Therapy" Designation

被引:58
作者
Kesselheim, Aaron S. [1 ]
Woloshin, Steven [2 ,3 ]
Eddings, Wesley [1 ]
Franklin, Jessica M. [1 ]
Ross, Kathryn M. [4 ]
Schwartz, Lisa M. [2 ,3 ]
机构
[1] Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, 75 Francis St, Boston, MA 02115 USA
[2] Dartmouth Inst Hlth Policy & Clin Practice, Ctr Med & Media, Lebanon, NH USA
[3] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA
[4] Amer Board Internal Med, Philadelphia, PA USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2016年 / 315卷 / 14期
关键词
D O I
10.1001/jama.2015.16984
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:1516 / 1518
页数:3
相关论文
共 4 条
[1]   A Randomized Trial Testing US Food and Drug Administration "Breakthrough" Language [J].
Krishnamurti, Tamar ;
Woloshin, Steven ;
Schwartz, Lisa M. ;
Fischhoff, Baruch .
JAMA INTERNAL MEDICINE, 2015, 175 (11) :1856-1858
[2]  
Medscape, ID ZYD APPR CLL LYMP
[3]  
Pfizer, TRUMENBA MEN GROUP B
[4]  
US Food and Drug Administration, BREAKTHR THER